Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.100
-0.040 (-3.51%)
Oct 29, 2025, 1:15 PM EDT
Interpace Biosciences Revenue
Interpace Biosciences had revenue of $9.23M in the quarter ending June 30, 2025, a decrease of -23.33%. This brings the company's revenue in the last twelve months to $45.45M, up 9.79% year-over-year. In the year 2024, Interpace Biosciences had annual revenue of $46.93M with 17.21% growth.
Revenue (ttm)
45.45M
Revenue Growth
+9.79%
P/S Ratio
0.11
Revenue / Employee
409.50K
Employees
111
Market Cap
4.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.93M | 6.89M | 17.21% |
| Dec 31, 2023 | 40.04M | 8.20M | 25.75% |
| Dec 31, 2022 | 31.84M | -1.28M | -3.86% |
| Dec 31, 2021 | 33.12M | 719.00K | 2.22% |
| Dec 31, 2020 | 32.40M | 8.18M | 33.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Interpace Biosciences News
- 6 weeks ago - Interpace Biosciences (IDXG) Showcases Promising Thyroid Nodule Testing Advances - GuruFocus
- 6 weeks ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 6 months ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 9 months ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 10 months ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq - GlobeNewsWire